In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented.

In a small study, patients with mild atopic dermatitis were recruited to wear an artificial intelligence (AI)-enabled, hand-mounted sensor that triggers feedback designed to decrease nocturnal ...

For adults, 2,678,888 controls were matched to 625,083 patients with atopic dermatitis (65.7% mild, 31.4% moderate, and 2.9% severe). They ranged in median age from 45 to 50, and were ...

Adults who were taking dupilumab for their atopic dermatitis also experienced significant improvements in their mild asthma, primarily in the first 16 weeks, according to a study published in ...

Roflumilast cream was an effective and safe treatment for mild to moderate atopic dermatitis in adults and children aged 6 years and older, Arcutis Biotherapeutics announced in a press release ...

Patients with mild to moderate atopic dermatitis and comorbid asthma or allergic rhinitis treated with crisaborole had significantly higher treatment success rates compared with vehicle control ...

More information: Albert F. Yang et al, Artificial Intelligence–Enabled Wearable Devices and Nocturnal Scratching in Mild Atopic Dermatitis, JAMA Dermatology (2025).

The approval of ZORYVE cream 0.15% for atopic dermatitis in Canadawas supported by positive results from the vehicle-controlled pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials, in which ...

Roflumilast cream 0.15% (ZORYVE ®) is approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of mild to moderate atopic dermatitis, in patients 6 years of age and older.

The INTEGUMENT-2 trial (ClinicalTrials.gov Identifier: NCT04773600) included 683 patients 6 years of age and older with mild to moderate atopic dermatitis involving at least 3% body surface area.